These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 2251653)

  • 1. [The late sequelae of the combined treatment of lymphogranulomatosis patients].
    Miasnikov AA
    Ter Arkh; 1990; 62(7):135-7. PubMed ID: 2251653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hodgkin's disease, splenectomy and secondary leukemia.
    Centurioni R; Brianzoni F; Leoni P; Danieli G
    Haematologica; 1993; 78(4):258-9. PubMed ID: 8294062
    [No Abstract]   [Full Text] [Related]  

  • 5. [Acute myeloid leukemia after treatment of Hodgkin's disease].
    Carneiro PC; Pereira ED; Mitteldorf CS; Martinez GA; Beitler B; Pozzi DH
    Rev Hosp Clin Fac Med Sao Paulo; 1989; 44(2):87-90. PubMed ID: 2616992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
    Villani F; Busia A; Villani M; Laffranchi A; Viviani S; Bonfante V
    Anticancer Res; 2009 Feb; 29(2):777-83. PubMed ID: 19331235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
    Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
    J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the risk of solid tumor following Hodgkin's disease.
    Maurizi Enrici R; Anselmo AP; Osti MF; Santoro M; Tombolini V; Mandelli F; Biagini C
    Haematologica; 1997; 82(1):57-63. PubMed ID: 9107084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
    Tan WY; Hu DS; Zeng FY; Song QB; Hu S; Wei L; Zhou LQ
    Ai Zheng; 2007 Dec; 26(12):1360-4. PubMed ID: 18076802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Radiation pericarditis following treatment of lymphogranulomatosis].
    Baĭsogolov GD; Shishkin IP; Shapiro IB
    Med Radiol (Mosk); 1983 Sep; 28(9):27-31. PubMed ID: 6688649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
    Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
    Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
    Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL
    Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of pediatric Hodgkin disease avoiding radiotherapy: excellent outcome with the Rotterdam-HD-84-protocol.
    Hakvoort-Cammel FG; Buitendijk S; van den Heuvel-Eibrink M; Hählen K
    Pediatr Blood Cancer; 2004 Jul; 43(1):8-16. PubMed ID: 15170884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acute leukemia in patients treated for Hodgkin's disease].
    Boccaccio P; Rosa F; Casciaro S; D'Elia P; Romagnoli M; Ghio R
    Recenti Prog Med; 1988 Jan; 79(1):32-7. PubMed ID: 3375542
    [No Abstract]   [Full Text] [Related]  

  • 15. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.
    Gerrard M; Cairo MS; Weston C; Auperin A; Pinkerton R; Lambilliote A; Sposto R; McCarthy K; Lacombe MJ; Perkins SL; Patte C;
    Br J Haematol; 2008 Jun; 141(6):840-7. PubMed ID: 18371107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program.
    Klimo P; Connors JM
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):34-40. PubMed ID: 2456621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
    Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
    J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Gobbi PG; Pieresca C; Cavanna L; Corbella F; Vallisa D; Federico M; Formisano R; Carotenuto M; Merli F; Callea V; Angrilli F; Silingardi V
    Haematologica; 1996; 81(6):503-12. PubMed ID: 9009437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
    Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
    J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.